University of Crete (UOC)
Συγκριτική μελέτη του mRNA της κυτταροκερατίνης-19, της MASPIN και του CEA στο αίμα ασθενών με καρκίνο του μαστού και διερεύνηση των μεταβολών τους κατά τη διάρκεια της χημειοθεραπείας ή και ορμονοθεραπείας
Abstract
dc:descriptionThe purpose of this study was to investigate and compare the diagnostic value of the detection of cytokeratin 19 (CK-19), carcinoembryonic antigen (CEA) and maspin mRNA by nested RT-PCR in the peripheral blood of women with breast cancer and to develop a highly sensitive quantitative RT-PCR hybridization assay for the determination of CK-19 mRNA in peripheral blood. The tumor cell lines MCF-7 and LOVO were used in an experimental tumor cell dilution model to determine the sensitivity of the nested RT-PCR for the 3 detection markers. RT-PCR for mRNA of CK-19, CEA and maspin was performed in the peripheral blood of 54 female healthy blood donors, 28 patients with hematologic malignancies, 31 with metastatic colorectal cancer, 75 with operable and 50 with metastatic breast cancer before receiving any cytotoxic chemotherapy. Nested RT- PCR for CK-19 mRNA presented the highest sensitivity by detecting 1 tumor cell amongst IO6 PBMC in 4 out of 5 experiments. CK-19 mRNA was detected in the peripheral blood of 3.7% of healthy blood donors, 14.3% of hematologic malignancies, 33.3% of operable and 42% of metastatic breast cancer patients. CEA mRNA was undetectable in female blood donors and was detected in blood samples of 3.5% of hematologic malignancies, 19.3% of colorectal cancer and 10% of breast cancer patients. Maspin mRNA was detected in 10.6% of operable and 14% of metastatic breast cancer patients. Maspin mRNA positivity correlated with tumor size in patients with early breast cancer (p= 0.027). Subsequently, peripheral blood from 148 patients with operable (stage I and II) breast cancer, obtained before the initiation of any adjuvant therapy, was tested for the presence of CK-19 mRNA-positive cells. For patients with stage I and II breast cancer, the detection of CK-19-positive cells in the peripheral blood before adjuvant therapy was associated with a 6-fold increased risk of relapse (p=0.001). In multivariate analysis, only the presence of CK-19 mRNA-positive cells in the peripheral blood and the number of involved axillary lymph nodes (≥ 4 lymph nodes) were independent prognostic factors associated with an increased risk of disease relapse. Conversely, the Cox proportional hazard analysis indicated that the detection of CK-19 mRNA-positive cells in the peripheral blood, the number of involved axillary lymph nodes and the status of ER expression by the tumor were the only important factors affecting the duration of DFT. Our results demonstrate that RT-PCR positivity for CK-19 mRNA is the most sensitive detection marker for tumor cells in operable and metastatic breast cancer and appropriate for use in clinical practice, although nested RT-PCR for maspin mRNA appears to be more specific. The molecular detection of CK-19 mRNA-positive cells by RT-PCR in the peripheral blood of patients with stage I and II breast cancer before the initiation of adjuvant therapy has an independent prognostic value as a marker of poor clinical outcome. We have also developed a highly sensitive quantitative RT-PCR hybridization assay for the determination of CK-19 mRNA in peripheral blood. Quantitation is based on the coamplification of CK-19 mRNA with a recombinant CK-19 RNA internal standard (CK-19 RNA-IS) through RT-PCR. The biotinylated amplification products are immobilized on streptavidin coated wells, hybridized with digoxigenin labeled probes and determined through an anti-digoxigenin antibody conjugated to alkaline phosphatase by luminometric detection. The hybridization assay was validated with samples containing total RNA from known amounts of CK-19 expressing cells (MCF-7) in the presence of total RNA isolated from peripheral blood mononuclear cells (PBMN) of healthy controls and a constant amount of CK-19 RNA-IS. Luminescence ratios for CK-19 mRNA and CK-19 RNA-IS were linearly related to the primary number of MCF-7 we had used. The overall reproducibility of the assay (between-run) varied between 7.4 and 24%. The method can clearly distinguish 10 MCF-7 cells (protocol A) and 1 MCF-7 cell (protocol B) in the presence of 106 normal PBMN and is highly specific as none of the healthy controls tested (n = 26) had detectable CK-19 mRNA levels, while 6 out of 14 breast cancer patients, with verified metastasis and under chemotherapy, were found positive.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2002
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Stathopoulou, Aliki
- Σταθοπούλου, Αλίκη
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/15822